Cyclosporine

Generic Name: Cyclosporine

Brand Names: Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis

Drug Type: Small Molecule

Chemical Formula: C_₆₂H_₁₁₁N_₁₁O_₁₂

CAS Number: 59865-13-3

Unique Ingredient Identifier: 83HN0GTJ6D

Background: Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication: Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions: Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production

Associated Therapies: -

Clinical Trials

Cyclosporine For The Treatment Of COVID-19(+)

Phase 2

Completed

Conditions: SARS (Disease)

Interventions: Other: Standard of Care Treatment
Drug: Cyclosporine

First Posted Date: 2020-07-30

Last Posted Date: 2023-07-20

Lead Sponsor: Bryan Burt, MD

Target Recruit Count: 47

Registration Number: NCT04492891

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Remdesivir
Drug: Imatinib Mesylate
Drug: Dexamethasone
Biological: dornase alfa
Drug: Celecoxib
Biological: IC14
Biological: narsoplimab
Drug: Cenicriviroc
Drug: Apremilast
Drug: Icatibant
Drug: Aviptadil
Drug: Cyproheptadine
Drug: Cyclosporine
Drug: Famotidine

First Posted Date: 2020-07-27

Last Posted Date: 2024-03-19

Lead Sponsor: QuantumLeap Healthcare Collaborative

Target Recruit Count: 1500

Registration Number: NCT04488081

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

and more 33 locations

Cyclosporine in Patients With Moderate COVID-19

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: Cyclosporine

First Posted Date: 2020-06-02

Last Posted Date: 2022-01-11

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 11

Registration Number: NCT04412785

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19

Phase 4

Completed

Conditions: COVID19 Infection

Interventions: Drug: Standard treatment
Drug: Cyclosporine

First Posted Date: 2020-05-19

Last Posted Date: 2022-07-14

Lead Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Target Recruit Count: 111

Registration Number: NCT04392531

Locations: 🇪🇸
Fundacion Jimenez Diaz, Madrid, Spain
🇪🇸
Clinica Universitaria de Navarra, Madrid, Spain
🇪🇸
Hospital General de Villalba, Villalba, Madrid, Spain

and more 4 locations

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Phase 4

Conditions: Hepatitis, Autoimmune
Primary Biliary Cholangitis
Immunosuppression

Interventions: Drug: Cyclosporin A
Drug: Mycophenolate Mofetil

First Posted Date: 2020-05-06

Last Posted Date: 2021-06-22

Lead Sponsor: West China Hospital

Target Recruit Count: 89

Registration Number: NCT04376528

Locations: 🇨🇳
WestChina Hospital, Chengdu, Sichuan, China

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Phase 1

Recruiting

Conditions: Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Undifferentiated Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine
Biological: Filgrastim
Procedure: Hematopoietic Cell Transplantation
Drug: Mitoxantrone
Drug: Idarubicin
Drug: Mycophenolate Mofetil
Drug: Fludarabine
Drug: Mycophenolate Sodium
Radiation: Total-Body Irradiation
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography
Procedure: X-Ray Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2020-05-05

Last Posted Date: 2024-11-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT04375631

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

Phase 4

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Cequa

First Posted Date: 2020-04-13

Last Posted Date: 2021-03-12

Lead Sponsor: Research Insight LLC

Target Recruit Count: 74

Registration Number: NCT04342988

Locations: 🇺🇸
Ophthalmic Surgeons & Consultants of Ohio, Columbus, Ohio, United States
🇺🇸
Harvard Eye Associates, Laguna Hills, California, United States
🇺🇸
Ophthalmology Associates, Saint Louis, Missouri, United States